Scarica l'app Stockscreener
0.288
2.80%
-0.0083
Dopo l'orario di chiusura:
.29
0.002
+0.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.2963
Aprire:
$0.2864
Volume 24 ore:
290.85K
Relative Volume:
0.14
Capitalizzazione di mercato:
$17.31M
Reddito:
$1.50M
Utile/perdita netta:
$-64.59M
Rapporto P/E:
-0.1725
EPS:
-1.67
Flusso di cassa netto:
$-55.17M
1 W Prestazione:
+2.02%
1M Prestazione:
-19.67%
6M Prestazione:
-91.06%
1 anno Prestazione:
-82.96%
Intervallo 1D:
$0.281
$0.3097
Intervallo di 1 settimana:
$0.2616
$0.3195
Portata 52W:
$0.2223
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Nome
Leap Therapeutics Inc
Settore
Industria
Telefono
617 252 4343
Indirizzo
47 THORNDIKE STREET, CAMBRIDGE, MA
Confronta LPTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.288 | 17.31M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-01-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-10-04 | Iniziato | Mizuho | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2020-06-29 | Iniziato | Piper Sandler | Overweight |
| 2020-02-11 | Iniziato | Robert W. Baird | Outperform |
| 2019-11-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-09-13 | Ripresa | Raymond James | Outperform |
| 2017-03-07 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Leap Therapeutics Inc Borsa (LPTX) Ultime notizie
2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs - R&D World
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock - BioWorld MedTech
HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - The Malaysian Reserve
Prostate Cancer Treatment Market Size in the 7MM was ~USD 12,300 million in 2023 and is expected to show positive growth by 2034, estimates DelveInsight - Barchart.com
Jane Street Group LLC Decreases Holdings in Dakota Gold Corp. (NYSE:DC) - Defense World
Jane Street Group LLC Purchases New Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Leap Therapeutics Reports Increased Q1 Losses - TipRanks
Metastatic Colorectal Cancer Pipeline Appears Robust With 150+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st
HC Wainwright Issues Optimistic Outlook for LPTX Earnings - Defense World
Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire
Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Cash-strapped Cambridge cancer biotech cuts 50% of its staff - NBC Boston
Cash-strapped Cambridge cancer biotech halves workforce - The Business Journals
Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment' - Fierce Biotech
Leap Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Leap Therapeutics Q1 Net Income USD -15.435 Million - marketscreener.com
Leap Therapeutics Reports First Quarter 2025 Financial Results | - GuruFocus
Leap Therapeutics Reports First Quarter 2025 Financial Results - Citizen Tribune
Leap TherapeuticsAnnounces 50% Workforce Reduction In Strategic RestructuringSEC Filing - marketscreener.com
Leap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates - Nasdaq
LEAP THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Purple Biotech Appoints Shai Lankry as Chief Financial Officer - The Manila Times
Leap Therapeutics (LPTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Leap Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Closing Bell Recap: Leap Therapeutics Inc (LPTX) Ends at 0.34, Reflecting a -12.39 Downturn - DWinneX
LPTX’s Market Whiplash: -85.46% YTD Decline, 37.04% Rise in 30 Days - investchronicle.com
75,800 Shares in Leap Therapeutics, Inc. (NASDAQ:LPTX) Acquired by LPL Financial LLC - Defense World
Enovix Corporation (NASDAQ: ENVX)’s Potential for Significant Price Increase in the Near Future - Marketing Sentinel
Quarterly Snapshot: Quick and Current Ratios for Leap Therapeutics Inc (LPTX) - DWinneX
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel - GuruFocus
Novel Cancer Cachexia Drug FL-501 Shows 3X Better Half-Life in Preclinical Data | LPTX Stock News - Stock Titan
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting - PR Newswire
Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatam - GuruFocus
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer | LPTX Stock News - GuruFocus
Leading Oncologist Reveals Game-Changing Phase 2 Results for Advanced Colorectal Cancer Treatment - Stock Titan
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer - PR Newswire
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn - Investing.com Canada
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn By Investing.com - Investing.com South Africa
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - Business Wire
HC Wainwright Expects Reduced Earnings for Leap Therapeutics - Defense World
Leap Therapeutics (NASDAQ:LPTX) Earns Neutral Rating from HC Wainwright - The AM Reporter
HC Wainwright Reiterates Neutral Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World
H.C. Wainwright maintains neutral on Leap Therapeutics stock By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Leap Therapeutics Inc Azioni (LPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):